myelodysplastic syndromes/главоболие

Линкът е запазен в клипборда

Изберете тип сортиране

Страница 1 от 40 резултата

Myelodysplastic syndrome and sagittal sinus thrombosis.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

After a 5-day illness beginning with severe headache, a 46-year-old man with myelodysplastic syndrome died of complications from cerebral venous thrombosis. Considering the underlying hematologic abnormality, multiple therapies, and potential for leukemic transformation, we suggest that patients

Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

In a phase I-II study, nine patients with myelodysplastic syndromes and concomitant severe transfusion-dependent cytopenias were treated with recombinant human interleukin-3 (rhIL-3) to improve hematopoietic function. Doses of rhIL-3 ranged from 250 micrograms/m2 to 500 micrograms/m2 and were given

A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

We performed a phase I/II study of recombinant human interleukin-3 (rhIL-3) in 21 patients with aplastic anemia (AA) or myelodysplasia (MDS). Patients received 21-day cycles of IL-3 (0.5, 1.25, 2.5, 5.0, or 10 micrograms/kg/d) by subcutaneous injection followed by a 10- to 14-day washout period.

Phase II study of roquinimex in myelodysplastic syndrome.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

A Phase II clinical trial was undertaken using roquinimex (Linomide) in patients with myelodysplastic syndromes (MDS). Roquinimex is an orally active drug with immunostimulating activities demonstrated in vitro and clinically. Seventeen patients with MDS were enrolled in the study. Eligibility was

A case of posterior reversible encephalopathy syndrome in a child with myelodysplastic syndrome following allogenic bone marrow transplantation.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Posterior reversible encephalopathy syndrome (PRES) is an uncommon but distinctive clinical-radiologic entity characterized by headache, seizures, visual disturbance, and altered mental function associated with reversible white matter edema affecting the posterior parietal and occipital lobes of the

Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

A multicenter phase II study was initiated to investigate the efficacy, toxicity and tolerability of an oral regimen of 9-cis retinoic acid (9CRA) as a differentiation-inducing agent stimulating both retinoic acid receptor (RAR) and retinoic X receptor (RXR). Thirty patients with myelodysplastic

All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

OBJECTIVE We conducted a study to evaluate the tolerance to and biologic effects of all-trans retinoic acid in patients with myelodysplastic syndrome. METHODS Thirty-nine patients with myelodysplastic syndrome were treated with oral all-trans retinoic acid for 6 weeks. Dose levels were 10, 25, 50,

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

The inhibition of histone deacetylase (HDAC) can induce differentiation, growth arrest, and apoptosis in cancer cells. This phase II multicenter study was undertaken to estimate the efficacy of belinostat, a potent inhibitor of both class I and class II HDAC enzymes, for the treatment of

Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Current guidelines support the use of erythropoiesis-stimulating agents for the treatment of anemia associated with low-risk myelodysplastic syndromes (MDS). METHODS Single-arm, open-label, multi-center, phase 2 trial that evaluated the efficacy and safety of darbepoetin alfa (DA) in

Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms (MDS/MPN) can be associated with giant cell arteritis (GCA). In this nationwide study by the "French Network of dysimmune disorders associated with hemopathies" (MINHEMON) the objective was to evaluate

Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Mast cells (MC) are multipotent hemopoietic effector cells producing diverse mediators like histamine, heparin, or tissue type plasminogen activator. We report a 75-year-old male patient with myelodysplastic syndrome (MDS) of recent onset (3 months' history) associated with a massive leukemic spread

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are adverse prognostic features in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDSs). VEGF is a soluble circulating angiogenic molecule that stimulates signaling via receptor tyrosine

EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyxeos, intended for the treatment of acute myeloid leukemia (AML). Vyxeos was designated as an orphan medicinal product

[Successful treatment with antiviral agents for human herpesvirus type 6 encephalitis following reduced intensity stem cell transplantation in a patient with myelodysplastic syndrome].

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

We report here a patient who suffered from PCR-confirmed human herpesvirus type 6 (HHV-6) encephalitis following reduced intensity stem cell transplantation (RIST) from her HLA-matched sibling donor. A 66-year-old woman with MDS-RA underwent RIST from her HLA-matched brother. Engraftment was

Modified luque instrumentation after myelomeningocele kyphectomy.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

METHODS Treatment of congenital kyphosis in myelomeningocele is a difficult problem. Current thinking supports kyphectomy and postoperative internal fixation. OBJECTIVE Since 1989, vertebral resection with modified Luque fixation has been the procedure of choice for correction of myelomeningocele

Предишна
1
2
3
Следваща

Присъединете се към нашата
страница във facebook

Herbal & Natural Medicine

Най-пълната база данни за лечебни билки, подкрепена от науката

Работи на 55 езика
Билкови лекове, подкрепени от науката
Разпознаване на билки по изображение
Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
Прочетете научни публикации, свързани с вашето търсене
Търсете лечебни билки по техните ефекти
Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания